Evidence map›Paper›PMID 33249050›Full record

ArticleJournal of pharmaceutical sciences2021

Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections.

Sergey V Valiulin, Andrey A Onischuk, Sergey N Dubtsov, Anatoly M Baklanov, Sergey V An'kov, Maria E Plokhotnichenko, Tatyana G Tolstikova, Galina G Dultseva, Vladimir L Rusinov, Valery N Charushin and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Triazavirin-A Novel Effective Antiviral Drug.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Sergey V ValiulinVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
Andrey A OnischukVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
Sergey N DubtsovVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
Anatoly M BaklanovVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
Sergey V An'kovVorozhtsov Institute of Organic Chemistry, SB RAS, Novosibirsk 630090, Russia.
Maria E PlokhotnichenkoVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
Tatyana G TolstikovaVorozhtsov Institute of Organic Chemistry, SB RAS, Novosibirsk 630090, Russia.
Galina G DultsevaVoevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia. Electronic address: dultseva@kinetics.nsc.ru.
Vladimir L RusinovPostovskii Institute of Organic Synthesis, UrB RAS, Yekaterinburg 620137, Russia.
Valery N CharushinPostovskii Institute of Organic Synthesis, UrB RAS, Yekaterinburg 620137, Russia.
Vasily M FominKhristianovich Institute of Theoretical and Applied Mechanics, SB RAS, Novosibirsk 630090, Russia.
Siberian Branch of the Russian Academy of Sciences · RUInstitute of Chemical Kinetics and Combustion · RUInstitute of Organic Synthesis · RUNovosibirsk Institute of Organic Chemistry · RUInstitute of Theoretical and Applied Mechanics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under pandemic-caused emergency, evaluation of the potential of existing antiviral drugs for the treatment of COVID-19 is relevant. Triazavirin, an antiviral drug developed in Russia for per-oral administration, is involved in clinical trials against SARS-CoV-2 coronavirus. This virus has affinity to epithelial cells in respiratory tract, so drug delivery directly in lungs may enhance therapeutic effect and reduce side effects for stomach, liver, kidneys. We elaborated ultrasonic method of triazavirin aerosol generation and investigated the inhalation delivery of this drug in mice. Mean particle size and number concentration of aerosol used in inhalation experiments are 560 nm and 4 × 10

Indexed as

Nebulizers and VaporizersAdministration, InhalationAdministration, OralAerosolsAnimalsAntiviral AgentsAzolesBiological AvailabilityCOVID-19 Drug TreatmentDrug Delivery SystemsDrug Elimination RoutesEquipment DesignHumansMaleMiceTriazinesAerosolsAntiviral AgentsAzolesriamilovirTriazinesTriazolesAntiviral drugBioavailabilityDrug aerosolElimination ratePharmacokineticsPulmonary drug deliveryTriazavirin

Identifiers

PMID33249050
PMCPMC7833544
OpenAlexW3110475791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.